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ScienceDirectmicroRNAs (miRNA) are small regulatory RNAs exerting
pleiotropic functions in virtually any immune cell-type.
Dozens of miRNAs with a known function in the immune
system constitute interesting drug targets for
immunomodulation. Chemical modifications of nucleic acid-
based miRNA mimics and inhibitors largely solved instability
issues but delivery to immune cells remains a major
challenge. However, recent success targeting the acidic
tumor microenvironment is very promising for inflammatory
diseases. Moreover, small molecules are being explored as
an interesting alternative. Although RNA is often considered
‘undruggable’ by small molecules recent progress
modulating miRNA function through small molecules is
encouraging. Computational approaches even allow
predictions about specific small molecule/RNA interactions.
Finally, recent clinical success demonstrates that drugs
targeting RNAs work in humans.
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Introduction
Genes encoding proteins have for a long time dominated
biomedical research and proteins were the main targets
for therapeutic interventions [1]. However, only a small
fraction of the mammalian genome actually encodes
proteins. Large parts of the genome that does not encode
proteins are transcribed and are collectively called ‘non-
coding’ RNAs [2]. In contrast to messenger RNAs
(mRNAs), which serve as intermediates to transfer infor-
mation from DNA to protein, the RNA transcripts them-
selves are the functional unit of non-coding genes.
Various classes of short and long non-coding RNAs con-
trol gene expression and the majority of causal genetic
variants driving autoimmune diseases are found in non-
coding regions illustrating the importance of non-coding
DNA [3].www.sciencedirect.com Here we focus on microRNAs (miRNAs), which belong to
the best-characterized small non-coding RNAs. We dis-
cuss progress published in the past few years in our
understanding of miRNA function in the immune system
with a particular focus on lymphocytes. It is beyond the
scope of this review to discuss each miRNA or immune
cell in detail. Instead, we highlight a few examples to
illustrate principles that are relevant from a therapeutic
perspective. We discuss potential therapeutic options and
various approaches to pharmacologically modulate
miRNA function to achieve immunomodulation. In prin-
ciple, the fact that therapeutic interventions have histori-
cally focused on proteins means that a lot of other targets
have been ignored. Thus, a treasure trove of a wide
variety of novel targets opens up. However, we also
discuss the challenges that need to be addressed when
targeting non-coding genes or their products in the im-
mune system.
microRNAs: important regulators of the
immune system
miRNAs are short posttranscriptional gene repressors,
which mediate their function through partial Watson-
Crick base-pairing with its target RNAs. Canonical
miRNAs are transcribed as long primary miRNAs (pri-
miRNAs) (Figure 1). The nuclear multiprotein micro-
processor complex (Dgcr8 and Drosha) then recognizes
and cleaves a hairpin in the pri-miRNA. The released
precursor miRNA (pre-miRNA) gets exported to the
cytoplasm where further processing occurs through Dic-
er. Several additional RNA binding proteins (RBPs)
such as LIN28 can influence miRNA biogenesis
[2,4]. Ultimately the mature, short miRNA duplex is
loaded onto Argonaute (Ago) to form a multiprotein
effector complex termed RNA-induced silencing com-
plex (RISC) [4]. Interaction of the miRNA with its
target RNA occurs in RISC and leads to translational
inhibition and later mRNA degradation [5]. Nucleo-
tides 2–7 termed the ‘seed’ region of a miRNA mostly
determine specificity for RNA targets. miRNAs with the
same seed region are grouped into families which target
the same RNAs. Finally, miRNA stability and turnover
are actively controlled by various mechanisms [6,7].
Several hundred miRNA genes exist as individual
miRNAs or clustered in the mammalian genome. Genetic
ablation of key genes in the miRNA biogenesis pathway
(e.g. Drosha, Dgcr8, Dicer, and Ago) results in cells devoid
of miRNAs. Cell-type specific ablation studies have
demonstrated a critical role for miRNAs in all examined
immune cells [8–10]. Thus, miRNAs as a class of regu-
latory short RNAs are critical for normal function ofCurrent Opinion in Pharmacology 2015, 23:25–31
26 Immunomodulation
Figure 1
RNA Polymerase II 
pri-miRNA pre-miRNAmiRNA genetranscription pre-miRNA
Exportin 5
miRNA
duplex mRNA 
Cytoplasm Nucleus 
miRNA
degradation
Dro
shaD
GC
R8 
Ago
RISC
complex
1 4
5
3
2
Target
inhibition
RB
P 
RB
P 
6
artificial
miRNA
mimic
Dicer
Current Opinion in Pharmacology
Pharmacologic intervention strategies to modulate miRNA biogenesis and function. miRNAs are transcribed by polymerase II into primary miRNAs
(pri-miRNA) which are processed into precursor miRNAs (pre-miRNA) by Drosha/Dgcr8. After export to the cytoplasm where further processing
occurs through Dicer the mature miRNA is loaded onto Argonaute (Ago) in a multiprotein complex termed RNA induced silencing complex (RISC). The
multi-step generation of canonical miRNAs allows modulation of miRNA expression using different approaches to interfere with specific steps of
miRNA biogenesis. (1) Small molecule inhibitor of transcription [44]. (2) Small molecule pri-miRNA processing inhibitor [48]. (3) pre-miRNA processing
inhibitor: small molecule or looptomir [39]. (4) Small molecule targeting the processing of pre-miRNA-21 by Dicer [47]. (5) Inhibitors of mature miRNA:
Antisense oligonucleotides; miRNA ‘sponges’; antagomir; seed targeting LNA-modified antimiRs [28]. (6) Delivery of artificial miRNA mimic.immune cell types regulating cell survival, proliferation,
differentiation and maintenance of cellular identity.
In contrast, functional characterization of individual
miRNAs or miRNA clusters has proven very challenging
[5]. Nevertheless, there is now a large body of literature
demonstrating the importance of individual miRNAs
regulating different cells of the immune system and
associations with human immunologic diseases [8,9,11].
Some miRNAs are transcribed individually whereas
others are generated from polycistronic transcripts that
encode multiple miRNAs. The miR-17-92 cluster can
serve as a paradigm to illustrate concepts that are broadly
applicable to other miRNAs as well. The pri-miR-17-92
transcript encodes for 6 different miRNAs with four
different seed families. Posttranscriptional processing
of the miR-17-92 cluster itself leads to differential ex-
pression of individual miRNAs within that cluster and
intracluster antagonism is functionally relevant since a
shifted balance of antagonistic miRNAs can contribute toCurrent Opinion in Pharmacology 2015, 23:25–31 pathogenesis [12,13]. Thus, combinatorial effects lead to an
enormously diverse context-dependent gene regulatory ca-
pacity [2]. Therefore, therapeutic modification of the ex-
pression of the entire cluster may result in different effects
than modulating the abundance of individual miRNA mem-
bers or modulation of processing of the cluster.
Promises of therapeutically targeting miRNAs
miRNAs are attractive therapeutic targets because they
fulfill several criteria defining a good drug target [1].
Although repression of individual target genes is gener-
ally mild, coevolution of miRNAs and their targets led to
regulation of entire pathways by individual miRNAs.
Hence, modulating miRNA expression promises to regu-
late entire pathways [14]. Importantly, individual miRNAs
can be drivers of disease. As an example, overexpression of
miR-17-92 is sufficient to drive lymphomagenesis and a
lupus-like lymphoproliferative disease whereas the cluster
is required for B and T cell differentiation of various
lymphocyte subsets [9,15,16,17,18,19]. Furthermore,www.sciencedirect.com
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is associated with multiple human immunologic diseases
[9,14]. To qualify as an ideal drug target a miRNA should
be pathogenic and exclusively expressed in a given tissue.
For instance miR-122 is highly and specifically found in the
liver [2]. Therefore systemic miR-122 blockade will only
have on-target effects in hepatocytes. In contrast, no
miRNA is known to be exclusively expressed in the
immune system although several miRNAs are enriched.
However, despite the absence of specific expression phar-
macologic blockade of selected miRNAs should be well
tolerated by most cells since miRNA-deficient animals
frequently do not display overt phenotypes [5,20]. An
important concept proposes that many miRNAs are re-
quired for biologic robustness during stress responses [21].
Thus, absence of a given miRNA will be tolerated under
homeostatic conditions but environmental perturbations
will in some cases result in adaptations that depend on the
miRNA. Therefore, during perturbations the lack of a
miRNA’s fine-tuning regulatory effect can result in observ-
able phenotypic consequences and thus reveal miRNA
function in miRNA-deficient organisms [21,22]. Thus,
identification of specific biologic processes that depend
on a particular miRNA promise to result in preferential
targeting of that cell type or process while sparing other
cells when the miRNA is inhibited. Tumors can become
dependent on the disease-driving miRNA, a process
termed oncomiR addiction. Inhibition of the pathogenic
miRNA leads to rapid tumor shrinkage [23]. As another
example, miR-17-92 is dispensable for development of
various T cell subsets under homeostatic conditions and
mice harboring miR-17-92-deficient regulatory T cells
(Treg) age normally without signs of Treg dysfunction
[17,19,24,25]. In contrast, induction of an acute immune
response results in much more severe disease in mice with
miR-17-92-deficient Treg than in mice with miR-17-92-
sufficient Treg. Mechanistically, antigen-specific effector
Treg were much more affected than the remaining Treg
[19]. Similarly, miR-17-92-deficient CD4+ T cells develop
normally but miR-17-92 is required for follicular helper T
cell (TFH) differentiation [17
,18]. Thus, antagonizing
miR-17-92 might be useful in TFH-driven autoimmune
disease. These results suggest that pharmacologic
miR-17-92 inhibition may preferentially target activated
T cells while sparing resting T cells. Ideally this could
lead to depletion/inactivation of pathogenic antigen-
specific T cells without changing the overall T cell
receptor repertoire.  However, both effector and regula-
tory T cells depend on miR-17-92 which makes it unpre-
dictable which way systemic pharmacologic miR-17-92
inhibition would shift the balance. Furthermore, germ-
line deletion of miR-17-92 leads to developmental
defects in mice and humans [24,26] but it is unknown
if miR-17-92 ablation in the adult or only transient
inhibition would also lead to predictable unwanted on-
target effects. In that case, cell-type specific delivery of
the inhibitor may circumvent the problem.www.sciencedirect.com Preclinical nucleic acid-based therapeutics
inhibiting miRNA function
Mature miRNAs can be inhibited by experimental over-
expression of miRNA binding sites (miRNA ‘sponges’) or
by pharmacologic administration of antisense oligonu-
cleotides (ASO) [27]. Therefore specific miRNA inhibi-
tors are relatively simple to design. Predictable specificity
(Watson-Crick base pairing) of the inhibitors for their
miRNA targets is a major advantage over, for example
small molecules whose specificity for their target is largely
unpredictable (Table 1). Therefore targeting miRNAs
with nucleic acid-based drugs promised to cut out medic-
inal chemistry from the drug development process which
should reduce time and costs. Indeed miRNA inhibitors
were rapidly developed and used experimentally. A num-
ber of chemical modifications improve stability against
nucleases, affinity of nucleotide-based miRNA inhibitors
and help to overcome the negative charge which inhibits
cell penetration [28]. Independent of their chemical
composition we will collectively refer to nucleic acid-
based miRNA inhibitors as antimiRs. Although miRNA
inhibition can readily be achieved in vitro, the biggest
challenge to inhibit miRNAs in vivo is delivery of anti-
miRs. To some degree this challenge is addressed by
conjugating the antimiRs to carriers or by packaging them
into various delivery vehicles [28,29,30]. Carriers do not
only allow or improve cellular uptake in vivo but they can
also be used to add specificity for target cells and organs.
However, guiding specific antimiR delivery to cells of
interest by conjugating the carriers to antibodies, ligands
or peptides further increases the complexity of the final
drug and thus the price. In a promising novel approach the
acidic environment of tumors induces a conformational
change in the carrier to allow cell permeation of the
antimiR. This approach generates selectivity for sites
of increased metabolism such as tumors or presumably
also sites of inflammation. AntimiR-155 treatment in a
miR-155 ‘addicted’ lymphoma model was effective and
more selectively targeted the diseased cells than the
current standard of care [31]. Since hypoxia occurs at
sites of inflammation this approach will likely also work in
miRNA-driven lymphoproliferative and autoimmune set-
tings [16,32].
Another promising class of antimiRs are very short locked
nucleic acid (LNA)-modified ASOs targeting miRNA
seed regions [33]. LNA seed family inhibitors inhibit
entire miRNA families rather than individual miRNAs
and even without carriers they have a good bioavailability
in vivo. LNA-modified antimiR-21 suppressed disease in
a lupus mouse model and psoriasis patient-derived skin
xenotransplants [34,35]. These studies are promising
because miR-21-deficient mice do not show detectable
defects suggesting that there will be limited unwanted
side effects. Furthermore, intradermal antimiR-21 deliv-
ery to the skin effectively improved disease [35]. This
illustrates that topic administration of antimiRs to readilyCurrent Opinion in Pharmacology 2015, 23:25–31
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Table 1
Comparison of nucleic acid-based drugs and small molecules to target miRNAs
Compound Class Pro Contra
Nucleic acid-based - Prediction of target specificity (Watson/Crick)
- Co-evolution of miRNAs and its targets:
modulate pathways/genetic networks
- Negatively charged
- Instability
- Delivery almost exclusively to the liver
- Non-specific stimulation of the immune system
- Expensive
- Little experience: new class of drugs
- Currently only parenteral or topic application
Small molecules - Good tissue penetration
- Large libraries are available
(5  106 compounds)
- Quite stable inside the cells
- Lots of clinical experience
(majority of clinically approved drugs)
- Relatively cheap
- Oral application
- Unpredictable specificity: Requires high
throughput screening followed by medicinal
chemistry. (Exception: Inforna algorithm allows
predictions) [48]accessible body surfaces (eyes, skin, oral cavity, airways,
vagina, rectum) is a viable alternative approach to over-
coming the challenges of systemic administration in vivo.
Therapeutically enhancing microRNA function
Depending on the clinical context it may be desirable to
pharmacologically enhance miRNA function, for example
to substitute lost miRNA function or to repress a miRNA-
regulated pathway. For instance the hypoxia-induced
miR-210 is a negative regulator of TH17 differentiation
[32]. Therefore delivering miR-210 mimics using the
above-mentioned approach to deliver to acidic environ-
ments might dampen TH17-driven inflammation [31
].
Induction of miR-146a is expected to have immunosup-
pressive effects since it is a negative regulator of several
immune cells and enhances regulatory T cell function
[9,10,36]. In contrast, transiently inducing miR-17-92
could potentially serve as an adjuvant during immuniza-
tion since it is induced by CD28-mediated costimulation,
is required for several CD28-dependent functions and it
is even sufficient to partially compensate for CD28 sig-
naling [16,17,18,19,37]. Induction of miR-17-92
should, however, only be transient since chronic over-
expression can drive disease in animal models [16].
Instead of delivering miRNA mimics induction of tran-
scription of endogenous miRNAs could be achieved using
CRISPR-based approaches [38]. However, this technolo-
gy is currently experimental and delivery of the necessary
molecules will likely face the same challenges as nucleic
acid-based drugs. Another interesting but poorly explored
approach is to target RNA structure or miRNA proces-
sing. Multi-step miRNA maturation and extensive sec-
ondary structures offer opportunities for therapeutic
intervention (Figure 1). Targeting the pre-let-7a-2 loop
was successfully achieved with a modified oligoribonu-
cleotide termed ‘looptomir’. The looptomir was designedCurrent Opinion in Pharmacology 2015, 23:25–31 to disrupt the inhibitory RBP Lin28 from binding to the
pre-let-7a-2 loop which enhanced let-7 processing [39].
Thus, multiple strategies can be pursued to increase
miRNA function.
Successful clinical trials
Nucleic acid-based therapeutics are generally well toler-
ated in humans and many clinical trials are ongoing
[28,29,40,41]. Short interfering RNAs (siRNAs) are short
double stranded RNAs that use the same cellular ma-
chinery as miRNAs to achieve gene repression referred to
as RNA interference (RNAi). Since siRNAs were ex-
plored before miRNAs the siRNA-based drugs tend to
be further advanced than miRNA modulating drugs but
successful clinical applications of the former should be a
good indicator for the latter [28,29,40]. Mipomersen, a
drug to treat a form of familial hypercholesterinemia
which targets apolipoprotein B mRNA through an
RNAse H-dependent mechanism was recently approved
as a systemically administered antisense drug. In addi-
tion, a single injection of an siRNA coupled to lipid
nanoparticles effectively led to transthyretin (TTR)
knockdown in patients with TTR Amyloidosis [42].
Similarly, miravirsen, an antisense inhibitor of miR-
122, resulted in a dose-dependent strong decrease in
hepatitis C viral load [43]. Thus, these important
proof-of-principle studies are very encouraging and sug-
gest that drugs targeting RNA work in humans. However,
despite major efforts to target multiple organs delivery is
most effectively achieved to the liver [28,29]. In fact,
according to publically available information most of the
companies specialized on RNAi/miRNA are targeting the
liver and none have major programs to treat immune
diseases anymore. Therefore, siRNA-based and miRNA
modulating drugs are likely to be on the market soon but
targeting miRNAs in the immune system might require
additional and specific efforts [30].www.sciencedirect.com
Targeting microRNAs for immunomodulation Jeker and Marone 29Alternatives to nucleic acid-based
therapeutics
In light of the challenging delivery of nucleic acid-based
drugs to immune cells alternative approaches to modulate
miRNA function are noteworthy. Small molecules (<500
molecular weight) are the cornerstone of the pharmaceu-
tical industry and overcome the delivery problem
(Table 1). A proof-of-principle study demonstrated the
successful identification of small molecules that modulate
miRNA function with a certain specificity [44]. The cost
for ease of delivery is to give up the predictable specificity
provided by nucleotide-based therapeutics. Thus, high
throughput screenings are required. However, RNA has
for a long time been considered ‘undruggable’ with small
molecules despite the fact that successful antibiotics
(aminoglycosides) work through direct interaction with
RNA. Due to extensive secondary structures RNA is
theoretically an attractive target. Possibly our limited
understanding of RNA structure and chemotypes that
preferentially interact with specific RNA structures may
account for this perception [45]. However, screening of a
small molecule library against a library of RNA motifs
identified chemotypes that preferentially bind RNA
which challenges this prevailing view. Moreover, com-
pared to other structures small molecules preferentially
bound to RNA hairpin loops which may be relevant to
target miRNA biogenesis (Figure 1) [46]. Indeed, based
on the known interaction of aminoglycosides with RNA,
particularly stem-loops and bulges, Bose et al. hypothe-
sized that aminoglycosides could modulate miRNA pro-
cessing. A small screen of aminoglycosides identified
streptomycin as a partially specific miR-21 inhibitor.
Mechanistically, streptomycin directly binds to the ter-
minal loop region of pre-miR-21 which blocks Dicer
processing (Figure 1) [47]. Thus, miRNA processing
can be modulated by direct binding of small molecules
to target RNAs. Moreover, a new computational approach
called Inforna can predict lead small molecule com-
pounds able to target a RNA of interest [48]. Predictions
were validated experimentally and demonstrated that
small molecule miRNA inhibition can be more specific
than a nucleic acid-based inhibitor. This powerful algo-
rithm combines available information from an RNA mo-
tif-small molecule interaction database with RNA
sequence and structure predictions/experimental data
and could be extended to any RNA. Thus, Inforna
combines the best of two worlds: predictability and ease
of delivery although the identified compounds were not
very potent [48].
In summary, small molecules can directly interact with
RNA to modulate miRNA processing, achieve remark-
able specificity and new approaches even allow predic-
tions of compound/RNA interactions. Since small
molecule interactions with RNA are very different from
interactions with proteins [49] specific efforts to deter-
mine RNA structure [50], RNA binding partners [51] andwww.sciencedirect.com growing databases of chemotypes interacting with RNA
structures might lead to the development of novel small
molecule immunomodulatory drugs that target miRNA
function.
Conclusions
From the first discovery of a miRNA in a worm more than
two decades ago we have come a long way. miRNAs are
important regulators of the immune system and consti-
tute attractive pharmacologic targets. Further research
will undoubtedly provide a more granular picture of
miRNAs and their targets in the immune system as well
as immune-mediated diseases. Delivery of nucleic acid-
based miRNA modulating drugs is extremely challenging
in the immune system but novel and alternative
approaches promise that miRNAs will ultimately become
drug targets in clinical practice. Future academic and
industrial research and development will need to focus
on improved in vivo delivery strategies. In addition, a
better understanding of RNA structure and interactions
between small molecules and RNA will pave the way for
small molecules to be targeted against RNA. The phar-
maceutical industry invested heavily in the pioneering
days of RNAi and miRNA research, then faced a phase of
disappointment and disinvestments but the recent clini-
cal success stories are sparking the field again and promise
to fuel the engine to the finish line of exploiting miRNAs
as targets for immunomodulation [52,53].
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